Emergent BioSolutions
EBSNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $6.05 Prior regular-session close from the quote source.
- $6.00–$6.12 Regular-session low and high so far today.
- 515.9K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Feb 25 projected Projected for 2027-02-25 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $4.36–$14.06 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own EBS if it replaces lumpy, expiring program revenue with recurring contracts or commercial product sales and avoids new regulatory or litigation shocks.
EBS price history
Loading recent earnings…
INVESTMENT THESIS
What must happen next
The 2025 operating‑income turnaround is sustainable only if recurring contract/product revenue replaces the prior one‑time or expiring program receipts that drove prior volatility.HoldingMateriality: High
operating_income was $100100000.0 (annual, period_end 2025-12-31) versus -108700000.0 in 2024 and -726400000.0 in 2023, showing a material swing to profitability. If true, the company will generate repeatable free cash and justify a multiple re‑rating; if false, profits will be episodic and the low valuation is deserved.
Watch: Loss or non‑renewal of a major government contract or large commercial customer leading to renewed revenue declines.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_income was $100100000.0 (annual, period_end 2025-12-31) versus -108700000.0 in 2024 and -726400000.0 in 2023, showing a material swing to profitability.
Open source ↗Revenue will not stabilize or grow unless Emergent secures new multi‑year government or commercial contracts to replace the declining program revenue that produced its prior higher revenue base.StrengtheningMateriality: High
revenue declined to $742900000.0 (annual, period_end 2025-12-31) from $1049300000.0 in 2023 and ~$1.12B+ in earlier years, showing a clear downshift in top line. Sustained top‑line stability is the prerequisite for predictable margins and cash flow; without it the business remains cyclical and high risk.
Watch: Failure to win/renew large government procurements or a shift in government purchasing strategy away from third‑party suppliers.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
revenue declined to $742900000.0 (annual, period_end 2025-12-31) from $1049300000.0 in 2023 and ~$1.12B+ in earlier years, showing a clear downshift.
Open source ↗The recovery in operating cash flow demonstrates the business can convert earnings to cash and materially reduce liquidity risk, provided receipts are recurring and not one‑time settlements.StrengtheningMateriality: Medium
operating_cash_flow improved from -206300000.0 (2023) to 58700000.0 (2024) to 170600000.0 (2025). Sustained positive cash flow reduces default/solvency risk, limits the need for dilutive financing, and allows investment in capacity or dividends/buybacks.
Watch: Large one‑time receipts (e.g., legal settlement, asset sale) that inflated 2025 cash flow but are not repeatable.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_cash_flow improved from -206300000.0 (2023) to 58700000.0 (2024) to 170600000.0 (2025).
Open source ↗A meaningful reduction in liabilities has improved solvency and reduced downside, making the company less likely to need dilutive financing if operating cash flow stays positive.StrengtheningMateriality: Medium
liabilities decreased from 1778600000.0 (2022) to 906900000.0 (2024) to 796000000.0 (2025), indicating substantial deleveraging or liability resolution. Lower liabilities and a stable equity base reduce bankruptcy/default tail risk and limit value destruction from forced financing.
Watch: Re‑emergence of large contingent liabilities (litigation, indemnities) or new debt raised under distress.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
liabilities decreased from 1778600000.0 (2022) to 906900000.0 (2024) to 796000000.0 (2025), indicating substantial deleveraging or liability resolution.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
The 2025 operating‑income turnaround is sustainable only if recurring contract/product revenue replaces the prior one‑time or expiring program receipts that drove prior volatility. If true, the company will generate repeatable free cash and justify a multiple re‑rating; if false, profits will be episodic and the low valuation is deserved.
Revenue will not stabilize or grow unless Emergent secures new multi‑year government or commercial contracts to replace the declining program revenue that produced its prior higher revenue base. Sustained top‑line stability is the prerequisite for predictable margins and cash flow; without it the business remains cyclical and high risk.
The recovery in operating cash flow demonstrates the business can convert earnings to cash and materially reduce liquidity risk, provided receipts are recurring and not one‑time settlements. Sustained positive cash flow reduces default/solvency risk, limits the need for dilutive financing, and allows investment in capacity or dividends/buybacks.
A meaningful reduction in liabilities has improved solvency and reduced downside, making the company less likely to need dilutive financing if operating cash flow stays positive. Lower liabilities and a stable equity base reduce bankruptcy/default tail risk and limit value destruction from forced financing.
All standing thesis claims
Original report summary
it replaces lumpy, expiring program revenue with recurring contracts or commercial product sales and avoids new regulatory or litigation shocks.
Bull case and bear case
Bull case and bear case for Emergent BioSolutions
Where the evidence on Emergent BioSolutions stands: Holding on the latest evidence (Nov 7, 2026). Of its 4 thesis points, 3 strengthening and 1 holding.
Bull case: what the evidence supports
The 2025 operating‑income turnaround is sustainable only if recurring contract/product revenue replaces the prior one‑time or expiring program receipts that drove prior volatility.
Revenue will not stabilize or grow unless Emergent secures new multi‑year government or commercial contracts to replace the declining program revenue that produced its prior higher revenue base.
The recovery in operating cash flow demonstrates the business can convert earnings to cash and materially reduce liquidity risk, provided receipts are recurring and not one‑time settlements.
A meaningful reduction in liabilities has improved solvency and reduced downside, making the company less likely to need dilutive financing if operating cash flow stays positive.
Bear case: what would count against it
Loss or non‑renewal of a major government contract or large commercial customer leading to renewed revenue declines.
Failure to win/renew large government procurements or a shift in government purchasing strategy away from third‑party suppliers.
Large one‑time receipts (e.g., legal settlement, asset sale) that inflated 2025 cash flow but are not repeatable.
Thesis-Break Engine
What has broken in Emergent BioSolutions’s thesis
Each break OptimistFi flagged on Emergent BioSolutions, dated — with what has historically followed the same kind of break across the market, not a forecast for Emergent BioSolutions.
- CEO / officer changecondition set before this filing
Across all companies, this kind of break has happened 16,849 times before. Those stocks trailed comparable companies by a median of 2% over the next six months, and 38% of them trailed it by 10 points or more.
Early warning
The break condition read on the trailing twelve months through Emergent BioSolutions’s latest quarterly report, ahead of the annual figure it is written on.
- Operating loss, trailing 12 months
Across all companies, this kind of early warning has happened 982 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 39% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MIXEDOther material event.
Emergent BioSolutions filed an SEC 8-K on 2026-11-04: Other material event. It is a dated development that tests the current thesis.
- MIXEDReported results of operations (earnings release).
Emergent BioSolutions filed an SEC 8-K on 2026-11-02: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MIXEDDirector or principal officer change.
Emergent BioSolutions filed an SEC 8-K on 2026-10-16: Director or principal officer change. It is a dated development that tests the current thesis.
RISKS / FALSIFIERS
What could break the thesis
- Loss or non‑renewal of a major government contract or large commercial customer leading to renewed revenue declines.
- Failure to win/renew large government procurements or a shift in government purchasing strategy away from third‑party suppliers.
- Large one‑time receipts (e.g., legal settlement, asset sale) that inflated 2025 cash flow but are not repeatable.
- Re‑emergence of large contingent liabilities (litigation, indemnities) or new debt raised under distress.
EBS news
Loading headlines…
FINANCIAL STATEMENTS
EBS income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
EBS: quick answers
- When does Emergent BioSolutions (EBS) report earnings next?
- Emergent BioSolutions's next results are projected for February 25, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 2, 2026. Earnings calendar
- What is EBS's short interest?
- As of October 30, 2026, 10.1M EBS shares were sold short, 19.6% of its shares outstanding, up 4.1% from the count before. At the stock's average daily volume that is 10 days to cover. FINRA publishes the count twice a month. EBS short interest history
- Have members of Congress traded EBS?
- 13 trades in EBS have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed EBS trade